tacrolimus

Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.

Cross Reference

Introduction

To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with tacrolimus?

tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with tacrolimus

MeSH term MeSH ID Detail
Inflammatory Bowel Diseases D015212 9 associated lipids
Reperfusion Injury D015427 65 associated lipids
Colitis D003092 69 associated lipids
Colonic Neoplasms D003110 161 associated lipids
Diabetes Mellitus, Type 1 D003922 56 associated lipids
Diabetes Mellitus, Type 2 D003924 87 associated lipids
Fatty Liver D005234 48 associated lipids
Cataract D002386 34 associated lipids
Diabetes Mellitus, Experimental D003921 85 associated lipids
Body Weight D001835 333 associated lipids
Per page 10 20 50 100 | Total 613

PubChem Associated disorders and diseases

What pathways are associated with tacrolimus

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with tacrolimus?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with tacrolimus?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with tacrolimus?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with tacrolimus?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with tacrolimus?

There are no associated biomedical information in the current reference collection.

NCBI Entrez Crosslinks

All references with tacrolimus

Download all related citations
Per page 10 20 50 100 | Total 15051
Authors Title Published Journal PubMed Link
Carcas-Sansuán AJ Limited sampling strategies for once daily tacrolimus exposure monitoring. 2016 Eur. J. Clin. Pharmacol. pmid:26939899
Herz S et al. Checkpoint inhibitors in chronic kidney failure and an organ transplant recipient. 2016 Eur. J. Cancer pmid:27614165
Hazama Y et al. Effect of Physiological Changes in the Skin on Systemic Absorption of Tacrolimus Following Topical Application in Rats. 2016 Biol. Pharm. Bull. pmid:26934927
Nakajima A et al. Effectiveness of tacrolimus in comparison with methotrexate or biologics in propensity score-matched patients with rheumatoid arthritis. 2016 Mod Rheumatol pmid:26934454
Iguchi A et al. Graft-versus-host disease (GVHD) prophylaxis by using methotrexate decreases pre-engraftment syndrome and severe acute GVHD, and accelerates engraftment after cord blood transplantation. 2016 Pediatr Transplant pmid:26526424
Fukuta T et al. Non-invasive evaluation of neuroprotective drug candidates for cerebral infarction by PET imaging of mitochondrial complex-I activity. 2016 Sci Rep pmid:27440054
Dugast E et al. Failure of Calcineurin Inhibitor (Tacrolimus) Weaning Randomized Trial in Long-Term Stable Kidney Transplant Recipients. 2016 Am. J. Transplant. pmid:27367750
Lim SW et al. Effect of Exendin-4 on Autophagy Clearance in Beta Cell of Rats with Tacrolimus-induced Diabetes Mellitus. 2016 Sci Rep pmid:27436514
Knight SR Intrapatient variability in tacrolimus exposure - a useful tool for clinical practice? 2016 Transpl. Int. pmid:27283231
Kolb M et al. Risk Factors for Subtherapeutic Tacrolimus Levels after Conversion from Continuous Intravenous Infusion to Oral in Children after Allogeneic Hematopoietic Cell Transplantation. 2016 Biol. Blood Marrow Transplant. pmid:26880117
Arreola-Guerra JM et al. Tacrolimus Trough Levels as a Risk Factor for Acute Rejection in Renal Transplant Patients. 2016 Ann. Transplant. pmid:26879833
Nie F et al. [Post-transplant kidney from C-III donation after cardiac death of children: a clinicopathologic study of 20 cases]. 2016 Zhonghua Bing Li Xue Za Zhi pmid:26879429
Dharnidharka VR et al. Differential risks for adverse outcomes 3 years after kidney transplantation based on initial immunosuppression regimen: a national study. 2016 Transpl. Int. pmid:27564782
Rostaing L et al. Successful Transplantation in ABO- and HLA-Incompatible Living Kidney Transplant Patients: A Report on 12 Cases. 2016 Ther Apher Dial pmid:27073167
Armand P et al. The addition of sirolimus to the graft-versus-host disease prophylaxis regimen in reduced intensity allogeneic stem cell transplantation for lymphoma: a multicentre randomized trial. 2016 Br. J. Haematol. pmid:26729448
Badr R et al. Assessment of global ischemic/reperfusion and Tacrolimus administration on CA1 region of hippocampus: gene expression profiles of BAX and BCL2 genes. 2016 Bratisl Lek Listy pmid:27546370
Hanaoka K et al. A chronic renal rejection model with a fully MHC-mismatched rat strain combination under immunosuppressive therapy. 2016 Transpl. Immunol. pmid:27545900
Matsa E et al. Transcriptome Profiling of Patient-Specific Human iPSC-Cardiomyocytes Predicts Individual Drug Safety and Efficacy Responses In Vitro. 2016 Cell Stem Cell pmid:27545504
Thao le Q et al. Pharmaceutical potential of tacrolimus-loaded albumin nanoparticles having targetability to rheumatoid arthritis tissues. 2016 Int J Pharm pmid:26657273
Mokuda S and Oiwa H Successful treatment of FKBP51-expressed multicentric reticulohistiocytosis using combination therapy with low-dose denosumab and tacrolimus. 2016 Scand. J. Rheumatol. pmid:26652057
Vadcharavivad S et al. Population pharmacokinetics of tacrolimus in Thai kidney transplant patients: comparison with similar data from other populations. 2016 J Clin Pharm Ther pmid:27191538
Yu H et al. Risk factors for new-onset diabetes mellitus after living donor kidney transplantation in Korea - a retrospective single center study. 2016 BMC Nephrol pmid:27473469
Niioka T et al. Influence of everolimus on the pharmacokinetics of tacrolimus in Japanese renal transplant patients. 2016 Int. J. Urol. pmid:26990259
Ikeya K et al. The Ulcerative Colitis Endoscopic Index of Severity More Accurately Reflects Clinical Outcomes and Long-term Prognosis than the Mayo Endoscopic Score. 2016 J Crohns Colitis pmid:26581895
Sakai R et al. A comparison of tacrolimus and cyclosporine combined with methotrexate for graft-versus-host disease prophylaxis, stratified by stem cell source: a retrospective nationwide survey. 2016 Int. J. Hematol. pmid:26800676
Milgrom SA et al. Graft-versus-host disease after radiation therapy in patients who have undergone allogeneic stem cell transplantation: two case reports. 2016 J Med Case Rep pmid:27465468
Pouché L et al. New challenges and promises in solid organ transplantation pharmacogenetics: the genetic variability of proteins involved in the pharmacodynamics of immunosuppressive drugs. 2016 Pharmacogenomics pmid:26799749
Constantinescu AA et al. Differential influence of tacrolimus and sirolimus on mitochondrial-dependent signaling for apoptosis in pancreatic cells. 2016 Mol. Cell. Biochem. pmid:27344165
Shao K et al. Different Effects of Tacrolimus on Innate and Adaptive Immune Cells in the Allograft Transplantation. 2016 Scand. J. Immunol. pmid:26524694
Cena T et al. De novo noncutaneous malignancies after kidney transplantation are associated with an increased risk of graft failure: results from a time-dependent analysis on 672 patients. 2016 Transpl. Int. pmid:27343849
Binkhathlan Z et al. Reutilization of Tacrolimus Extracted from Expired Prograf® Capsules: Physical, Chemical, and Pharmacological Assessment. 2016 AAPS PharmSciTech pmid:26729529
Gardiner KM et al. Multinational Evaluation of Mycophenolic Acid, Tacrolimus, Cyclosporin, Sirolimus, and Everolimus Utilization. 2016 Ann. Transplant. pmid:26729299
Chacon A and Mercer J Successful management of angiolymphoid hyperplasia with eosinophilia in a split-face trial of topical tacrolimus and timolol solution. 2016 G Ital Dermatol Venereol pmid:25014586
Riegersperger M et al. The Effect of ABCB1 Polymorphisms on Serial Tacrolimus Concentrations in Stable Austrian Long-Term Kidney Transplant Recipients. 2016 Clin. Lab. pmid:28164520
Pizzo HP et al. Sirolimus and tacrolimus coefficient of variation is associated with rejection, donor-specific antibodies, and nonadherence. 2016 Pediatr. Nephrol. pmid:27286686
Fernández de Castillo Torras L et al. Treatment with ulipristal acetate (Esmya(®)) and plasma levels of tacrolimus: a case report. 2016 Eur. J. Obstet. Gynecol. Reprod. Biol. pmid:27282803
Ferjani H et al. The evaluate and compare the effects of the Tacrolimus and Sirolimus on the intestinal system using an intestinal cell culture model. 2016 Toxicol. Mech. Methods pmid:26460985
Serrano-Mollar A et al. Safety and Tolerability of Alveolar Type II Cell Transplantation in Idiopathic Pulmonary Fibrosis. 2016 Chest pmid:27020420
Seok J et al. Recalcitrant steroid-induced rosacea successfully treated with 0.03% tacrolimus and 595-nm pulsed dye laser. 2016 Eur J Dermatol pmid:27193042
Sisti A et al. Effectiveness and safety of topical tacrolimus monotherapy for repigmentation in vitiligo: a comprehensive literature review. 2016 An Bras Dermatol pmid:27192518
Rao B et al. Use of Everolimus After Multivisceral Transplantation: A Report of Two Cases. 2016 Transplant. Proc. pmid:27109983
Chang HK et al. Ten-Year Experience With Bowel Transplantation at Seoul St. Mary's Hospital. 2016 Transplant. Proc. pmid:27109981
Baraldo M Meltdose Tacrolimus Pharmacokinetics. 2016 Transplant. Proc. pmid:27109969
Felix MJ et al. Time-Dependent and Immunosuppressive Drug-Associated Adverse Event Profiles in De Novo Kidney Transplant Recipients Converted from Tacrolimus to Sirolimus Regimens. 2016 Pharmacotherapy pmid:26799522
Adler M et al. A Quantitative Approach to Screen for Nephrotoxic Compounds In Vitro. 2016 J. Am. Soc. Nephrol. pmid:26260164
Kishida N et al. Increased Incidence of Thrombotic Microangiopathy After ABO-Incompatible Living Donor Liver Transplantation. 2016 Ann. Transplant. pmid:27956735
Jimbo H et al. Telangiectatic lichen sclerosus on the cheek successfully treated with topical tacrolimus. 2016 Eur J Dermatol pmid:27033557
Shimizu K et al. Specific delivery of an immunosuppressive drug to splenic B cells by antigen-modified liposomes and its antiallergic effect. 2016 J Drug Target pmid:27030163
Ha DH et al. Potential differentiation ability of gingiva originated human mesenchymal stem cell in the presence of tacrolimus. 2016 Sci Rep pmid:27721434
Taşoğlu Ö et al. Pregabalin: A New Adjunct in Calcineurin Inhibitor Pain Syndrome Treatment. 2016 Prog Transplant pmid:27312682